Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Kadcyla, Bayer’s Xofigo Head Latest Positive Opinions In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK’s once-daily combination inhaler Relvar Ellipta along with J&J’s diabetes therapy Invokana, Novo Nordisk’s hemophilia therapy NovoEight and Gilead HIV therapy Vitekta complete the list of six new medicines recommended for approval by the CHMP, Europe’s top scientific advisory panel.

You may also be interested in...



Patient Engagement Helped Roche’s Kadcyla Get Reimbursement In Scotland

Roche has finally gained a positive recommendation from a health technology assessment body in the UK for its advanced breast cancer therapy, Kadcyla. The Scottish Medicines Consortium gave the product the all-clear after the quality-of-life benefits were highlighted by patients and doctors. It’s future in England is still unclear.

Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division

Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.

Advair Generics Likely Lucrative Product For Few That Can Clear High Bar

With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel